Active	Status	Sponsor type	Region	Phase	Filter
9 Active 4 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stefano, Valerio De
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma	Completed	1	15	Europe, US, RoW	Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide	Takeda, Takeda Development Center Americas, Inc.	Multiple Myeloma	06/24	06/24
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19	Recruiting	N/A	552	Europe, US, RoW		Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net	Myeloproliferative Neoplasm, COVID	02/22	08/22
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)	Recruiting	N/A	319	Europe	Ropeginterferon alfa-2b, Besremi	FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS	Polycythemia Vera	09/26	12/26
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance	Recruiting	N/A	250	Europe		Ospedale di Circolo - Fondazione Macchi	SARS-CoV-2 Infection, Hematological Malignancies	10/22	10/22
SAPIENT, NCT06262750: Evaluation of Safety and Efficacy of Anticoagulation Treatment in Patients With Splanchnic Vein Thrombosis: Study	Recruiting	N/A	170	Europe		Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Splanchnic Vein Thrombosis	12/23	11/25
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.	Recruiting	N/A	617	Europe, RoW		FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline	Myelofibrosis	12/25	12/28
NCT05694325: Biologic Characterization of Patients With ITP	Recruiting	N/A	200	Europe	peripheral blood and bone marrow withdrawal	Gruppo Italiano Malattie EMatologiche dell'Adulto	Immune Thrombocytopenia	11/26	11/26
NCT06028087: Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment	Not yet recruiting	N/A	736	NA		Gruppo Italiano Malattie EMatologiche dell'Adulto	Multiple Myeloma, Diagnosis	12/28	12/28